The Drug Development Pipeline, 2002
ALX40-4C ~ Allelix Pharmaceuticals ~ Formulation difficulties, lack of efficacy
AMD3100 ~ AnorMed Inc. ~ Cardiac arrhythmias at high doses, lack of efficacy at low
PD-178390 ~ Parke-Davis ~ Casualty of Pfizer merger
CI-1012 ~ Parke-Davis ~ Casualty of Pfizer merger
PNU-142721 ~ Pharmacia & Upjohn ~ Casualty of P&U’s decision to leave HIV field
NSC 651016 ~ Pharmacia & Upjohn ~ Casualty of P&U’s decision to leave HIV field
UC781 ~ Biosyn Inc. ~ Being developed as topical microbicide
zintevir/AR-177 ~ Antigenics (formerly Aronex) ~ Terminated subsequent to takeover and poor results
(-)dOTC/BCH-10618/SPD754 ~ Shire Pharmaceuticals PLC ~ Deaths in monkeys
capravirine/S-1153/AG-1549 ~ Agouron (Pfizer) ~ Vasculitis in dogs may mean curtains for cap.
mozenavir/DMP-450 ~ DuPont (now BMS) ~ Electro-cardiographic abnormalities in animals
T-1249 ~ Trimeris/Roche ~ Phase I; longer half-life may allow QD dosing
tipranavir ~ Boehringer-Ingelheim ~ "Trinity of major obstacles,” paper at summer IAS
VX-175/GW433908 ~ Vertex/GlaxoSmithKline ~ Amprenavir prodrug, PK dose-ranging at 8CROI
SCH-C ~ Schering/Praecis ~ Results of 8-week study presented at 9CROI
PRO 542 ~ Progenics Pharmaceuticals ~ Phase II, being studied in combination with T-20
DPC-083 ~ DuPont (now BMS) ~ Eyed to hit market in 2003; paper at 7CROI
TMC-125 ~ Tibotec/Virco ~ "Amazing potency" unveiled at 9CROI; to file NDA 2004
TMC-120 ~ Tibotec/Virco ~ Paper at 8CROI
TMC-126 ~ Tibotec/Virco Paper at 8CROI
DPC-961, DPC-963 ~ DuPont (BMS) ~ Atazanavir may take priority over these
Calanolide-A ~ SarawakMed ~ Paper on this at 7CROI
GPG-NH2 ~ Tripep AB/Karolinska Institute ~ Early activity in humans not too impressive
SCH-D ~ Schering/Praecis ~ Follow-up compound to SCH-C
UK-427,857 ~ Pfizer ~ Said to be moving into Phase I "soon”
DPC-681, DPC-684 ~ DuPont (BMS) ~ Phase I studies on-going; paper at 8CROI
AMD-3465, 8445, 8664 ~ AnorMed ~ AMD8664 is orally available analogue of AMD3100
TAK-779 ~ Takeda Pharmaceuticals ~ Being studied in combination with T-20
HE2000 ~ ~ Hollis-Eden PharmaceuticalsPhase I/II enrolling in U.S.; info from company, other
PRO 140 ~ Progenics Pharmaceuticals ~ Moving into Phase I/II; press release
PRO 367 ~ Progenics Pharmaceuticals ~ Phase I recently completed
Hu5A8 ~ Tanox Biosystems, Inc. ~ Phase I clinical study began 8/1/01
PEHRG214 ~ Virionyx ~ Phase I at Boston Deaconess Hospital, 3/01
HIV NCp7 ~ Achillion Pharmaceuticals ~ Pre-clinical; also in Phase I for HBV; see CRADA announcement
SPD-756 ~ Shire Pharmaceuticals PLC ~ Formerly BCH-13520; company press release
Fd4C/ACH-126,443 ~ Achillion Pharmaceuticals ~ L. Dunkle on this, but will it go the way of other ‘F’ drugs?
5-helix ~ Howard Hughes Medical Inst. ~ Science 2001, 291: 884-888
ADA (azidocarbonamide) ~ Hubriphar ~ Phase I/II: AIDS 2001, 15:33-45
S1360 ~ Shionogi Pharmaceuticals ~ Animal safety data at 9CROI; Human study underway
TAK-449 ~ Takeda Pharmaceuticals ~ Company officials refused request for information
T-649 ~ Trimeris/Roche ~ Similar to T-1249; paper at 7/01 IAS meeting
BMS-806 ~ Bristol-Myers Squibb ~ In vitro results at 9CROI; Human trial to start later this year
Merck integrase inhibitor ~ Merck ~ Phase I studies to commence March 2002
Merck prime-boost vaccine ~ Merck ~ Safety trials in HIV-negative volunteers currently underway
AG-1776/JE-2147 ~ Agouron (Pfizer) ~ All appearances suggest this drug is history.
L-708,906, L-731,988 ~ Merck ~ Hazuda, D.J., et al. Science 287(Jan. 28):646 (also, Science News)
Didox, Trimodox ~ Molecules for Health Ribonucleotide reductase inhibitors – circa 1995
AOP-RANTES ~ Gryphon Sciences ~ Animal (mouse) data only, J Virol 5/99, paper as summer IAS
FP-21399 ~ Lexigen Pharmaceuticals ~ Bruce Dezube again: J Infect Dis 2000 182:607-10
PRO2000 ~ Genetics (formerly Procept) ~ Being tested as topical microbicide at Fenway Center
HGTV43 ~ Enzo Biochem, Inc. ~ Paper at summer IAS meeting
SJ-3366 ~ Samjin Pharmaceuticals Ltd. ~ Paper at 14th Intl. Conf. on Antiviral Research, 4/01
Treatment Index